Press Releases

October 21, 2009

Vivalis confirms its sound financial position 2009 nine-month revenue: €3.8 million Net cash stable in third quarter at €24.7 million

October 13, 2009

Vivalis accelerates marketing of the EB66® cell line in North America

September 29, 2009

GlaxoSmithKline signs an agreement with Kaketsuken to codevelop cell-culture based influenza vaccines in Japan based on Vivalis EB66® cell line

September 14, 2009

Participant at the Midcap Event in Paris on September 21st and 22nd 2009

September 8, 2009

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer

August 31, 2009

2009 first half: substantial improvement in performance Operating income: €4.9 million (+86%) Confirmation of 2009 targets: Net cash at year-end 2009 > €20 million Signature of 10 license agreements

August 25, 2009

Finalists from Germany, France and Switzerland nominated for the EUROPEAN BIOTECHNICA AWARD 2009

July 22, 2009

ROBUST FIRST-HALF GROWTH: NET CASH SURPLUS OF €1.8 MILLION IN THE FIRST HALF SOLID CASH POSITION AT 06/30/09 OF €24.5 MILLION +€3 MILLION RECEIVED FROM OSEO ISI IN EARLY JULY

July 15, 2009

VIVALIS AND INTERVET/SCHERING-PLOUGH ANIMAL HEALTH SIGN A COMMERCIAL LICENSE TO USE THE EB66® CELL LINE FOR VIRAL VACCINE PRODUCTION AND EVALUATE THE PLATFORM FOR 12 NEW VACCINES.

June 30, 2009

NEW RESEARCH LICENSE AGREEMENT FOR ANTIBODIES 2009 COMMERCIAL TARGETS RAISED: 10 NEW LICENSE AGREEMENTS

1
…
44
45
46
47
48
…
51